Identifying Drug Repurposing Opportunities in Oncology

Research output: Contribution to journalReview articlepeer-review


The never-ending explosion in the cost of new oncology drugs is reducing in many countries the access to the most recent, effective anticancer therapies and represents a significant obstacle to the design and realization of combinatorial trials. Already approved, anticancer and nonanticancer drugs can be considered for in silico, preclinical, and clinical repurposing approaches and offer the significant advantages of a potentially cheaper, faster, and safer validation. This review discusses recent advances and challenges in the field.

Original languageEnglish
Pages (from-to)82-87
Number of pages6
JournalCancer Journal (United States)
Issue number2
Publication statusPublished - Mar 1 2019


  • Anticancer drugs
  • drug repurposing
  • oncology drugs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Identifying Drug Repurposing Opportunities in Oncology'. Together they form a unique fingerprint.

Cite this